In a meta-analysis of several cardiovascular outcome trials regarding SGLT2i and GLP-1 agonists, Zelniker et al. found that MACE reduction was restricted to SGLT2i-administered patients with established atherosclerosis [191], while Wright et al. demonstrated that both SGLT2i monotherapy and SGLT2–GLP-1 agonist combination therapy may have a beneficial primary MACE risk reduction [192]. The gene discussed is SLC5A2; the disease is atherosclerosis.